Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of rosuvastatin + ezetimibe combination therapy in primary hypercholesterolemia
KCT0001831Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Nov 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosuvastatin and ezetimibe in hypercholesterolemia, sponsored by Hanlim Pharm. Started Nov 2014; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on KCT0001831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001831.